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COVID-19 vaccinations 
in patients with 
inflammatory bowel 
disease
Advances in the treatment of patients 
with inflammatory bowel disease 
(IBD) have substantially improved 
disease activity and quality of life, 
and reduced hospitalisation rates 
and the need for surgery. However, 
prolonged immunosuppression in 
these patients can result in increased 
susceptibility to opportunistic 
infections. Many of these infections 
are preventable through vaccination 
and immunisation strategies that 
should be undertaken as early as 
possible after diagnosis, because 
the risk of opportunistic infections 
increases following the first year of 
immunosuppressive therapy.1
The COVID-19 pandemic has led to 
substantial concerns for patients with 
IBD who are on immunosuppressive 
medications, many of whom are 
using additional protective measures. 
Although early COVID-19 studies have 
suggested that immunosuppressive 
medications are safe, robust and 
reproducible data are not available 
to adequately risk stratify patients 
with IBD, and current measures are 
mostly based on observational studies 
and theoretical risk.2 Large scale, 
prospective, population-based registry 
studies and meta-analyses have 
identified key risk factors associated 
with a higher probability of mortality 
from COVID-19, including age, 
socioeconomic deprivation, diabetes, 
respiratory disease, obesity, and being 
from a Black, Asian, or other minority 
ethnic group.3
One of the best ways to mitigate 
against the risk of COVID-19 is the 
rapid development of safe and 
effective vaccines. Although initial 
phase 1/2 studies are promising,4 
patients on immunosuppressant 
medications have largely been 
excluded from these studies, creating 
potential future concerns regarding 
safety and generalisability of outcomes 
for individuals with IBD.
To achieve a sufficient degree 
of herd immunity, vaccination 
programmes are primarily successful 
only when there are high rates 
of coverage and acceptance. The 
importance of patients with IBD 
being included in vaccine trials is 
compounded by the concern that 
these patients have a lower response 
to vaccinations and that vaccinations 
are generally underused in this 
population. Melmed and colleagues5 
showed that in patients with IBD there 
was an uptake of only 22–46% for the 
influenza vaccination, and a mere 
9% were vaccinated for pneumococcal 
pneumonia, despite both vaccines 
being recommended in the British 
and European IBD guidelines for 
vaccinating patients.6 A patient survey 
showed a perceived lack of benefit 
from vaccination as the most frequent 
reason for low vaccine uptake, as well 
as concerns regarding side-effects, 
risk of disease flares, needle aversion, 
and inconvenience.7 However, in the 
present pandemic, both perception 
of risk and health awareness might be 
very different, with implications for 
vaccine acceptance.
In patients with IBD who were 
vaccinated against influenza, an 
immune response was induced, but 
use of concomitant infliximab and 
immunomodulatory therapy were 
associated with inadequate rates of 
seroconversion.8 In adult populations 
vaccinated with the pneumococcal 
vaccine PSV-23, an impaired immune 
response was shown in patients with 
Crohn’s disease taking combination 
immunosuppressive therapy.1 Other 
vaccines such as those against 
hepatitis A and B virus, tetanus, and 
herpes zoster have also been shown 
to be potentially less effective in 
patients with IBD than in control 
groups.9
The extent to which medications 
might affect vaccine response, 
independent of underlying disease 
activity, is unclear. Of note, concurrent 
anaemia, which is a common finding 
in patients with active IBD, might 
impair response to vaccinations.9 
There is therefore an urgent need 
for better understanding of both the 
effectiveness of potential vaccines 
against severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) 
in patients with underlying health 
conditions, as well as the potential 
impact of effective disease control on 
rates of vaccine response.
Currently, the candidate vaccines 
in phase 3 trials include inactivated, 
mRNA, or vector-based approaches. 
The classic inactivated or live-
attenuated vaccines raise safety 
concerns due to possible induction of 
the disease. However, the ChAdOx1 
nCoV-19 trial vaccine uses a replication-
deficient chimpanzee adenovirus to 
deliver a SARS-CoV-2 protein to induce 
a protective immune response. This 
vaccine seems to be promising for 
patients with IBD because adenovirus 
vectors do not integrate the viral 
genomic DNA into the host’s genome, 
are highly immunogenic, and can 
induce robust innate and adaptive 
immune responses. The same adeno-
virus vaccine platform is also being 
assessed for use against malaria, 
HIV, influenza, and Ebola virus.10 
Nevertheless, the phase 1/2 trials of 
the ChAdOx1 nCoV-19 vaccine were 
done on young, healthy volunteers and 
as such do not address the potential 
immunity concerns in patients 
with chronic diseases or those on 
immunosuppressants.4 Moreover, 
we cannot assume that data on one 
vaccine type in a specific group of 
people can be extrapolated to other 
vaccine types.
There needs to be a stronger 
emphasis on vaccinating patients with 
IBD within the broader health-care 
preventative scheme. It is important 
that these factors are considered 
when policy makers and national 
health services start to design and 
develop future COVID-19 vaccination 
programmes. Equitable access to 
COVID-19 vaccination programmes 
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such disruption, using a standardised 
questionnaire (appendix pp 1–3). 
The number of patients reviewed 
monthly at the hepatitis clinics fell 
substantially from January to 
April, 2020, by 71% in Burkina Faso, 
95% in Tanzania, and 83% in The 
Gambia for new cases, and by 73% in 
Burkina Faso, 77% in Tanzania, and 
89% in The Gambia for patients in 
follow-up (appendix p 4). To exclude 
any annual seasonal effects, we 
compared the number of viral hepatitis 
cases (new patients and patients in 
follow-up) in 2020 against those seen 
during the same period last year (Jan 1 
to April 30, 2019) in The Gambia and 
found no significant fluctuation in 
cases (data not shown).
Across these countries, doctors 
consistently cited the patient’s fear of 
contracting severe acute respiratory 
syndrome coronavirus 2 at clinics as a 
primary reason for the drop in patient 
numbers. The decrease in number of 
outpatient visits seems to have 
started in February, 2020, preceding 
confir mation of the first COVID-19 
cases in these countries (from the 
second to third week of March, 2020) 
and implementation of public health 
measures limiting social contacts by 
the respective governments (in March 
and April, 2020). In Burkina Faso, the 
number of patients regularly moni-
tored for chronic viral hepatitis 
steadily fell over this period, even 
though clinics were maintained and 
treating doctors encouraged patients 
to be retained in care. By contrast, in 
Tanzania and The Gambia, hepatitis 
clinics were temporarily closed at the 
end of March, 2020, to prepare for the 
COVID-19 epidemic, and staff at 
hepatitis services were relocated to 
support COVID-19 preparedness, to 
receive patients who were febrile with 
a suspicion of COVID-19, and to 
mitigate COVID-19 outbreaks. Of the 
essential diagnostic tests to manage 
chronic hepatitis, rapid tests for 
HBsAg, alanine aminotransferase, 
and haematology were available 
without any disruption throughout 
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should be endorsed. If this is not 
feasible, then we propose that future 
community vaccination programmes 
support and promote vaccines that 
can be used by the high-risk cohort of 
patients with IBD.
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Effect of the COVID-19 
pandemic on viral 
hepatitis services in 
sub-Saharan Africa
The global response to limit the 
spread of COVID-19 has diverted 
attention and resources from existing 
local health priorities, particularly in 
countries of low and middle income 
(LMICs).1 As highlighted in a Comment 
in The Lancet Gastroenterology & 
Hepatology by Neil Gupta and 
colleagues,2 the collateral damage on 
efforts to address the viral hepatitis 
epidemic in sub-Saharan Africa is of 
high concern. However, the potential 
effect of COVID-19 on viral hepatitis 
services has been poorly documented.2 
We have recorded a striking decrease 
in use of outpatient services by 
patients with chronic hepatitis in three 
countries in sub-Saharan Africa. We 
retrospectively counted the number of 
new and known cases of chronic 
hepatitis B virus (HBV) or hepatitis C 
virus (HCV) infection seen at the main 
referral hospitals in Burkina Faso 
(Yalgado-Ouédraogo Hospital and 
Bodogodo Hospital, Ouagadoudou; 
and Souro-Sanou Hospital, Bobo-
Dioulasso), Tanzania (Muhimbili Na-
tional Hospital, Dar es-Salam), and The 
Gambia (Medical Research Council 
Clinical Services, Fajara) from Jan 1 to 
April 30, 2020, a period covering the 
time before and during the COVID-19 
pandemic. We also asked a doctor 
in charge of hepatitis services at each 
centre about the type of clinical 
and laboratory services that were 
disrupted, and plausible reasons for 
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